SCHEMBL20119913

SCHEMBL20119913

c1coc(CNc2ncnc3[nH]ccc23)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.66
SMN1; SMN2 Q16637 9/20 0.63
HTT P42858 7/20 0.61
RAB9A P51151 3/20 0.61
HIF1A Q16665 2/20 0.61
LMNA P02545 6/20 0.60
TSHR P16473 5/20 0.59
ALOX15 P16050 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CYP1A2 P05177 2/20 0.59
TP53 P04637 2/20 0.59
ADORA3 P0DMS8 1/20 0.59
KDR P35968 1/20 0.59
MAPK1 P28482 7/20 0.57
ALDH1A1 P00352 5/20 0.57
HPGD P15428 4/20 0.57
NOD2 Q9HC29 1/20 0.57
AURKA O14965 1/20 0.55
RPS6KB1 P23443 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL22346221 0.99 POLB (0.64) POLBSMN1; SMN2HTTRAB9AHIF1A
SCHEMBL20119690 0.80 SMN1; SMN2 (0.64) POLBSMN1; SMN2HTTRAB9AHIF1A
SCHEMBL17009430 0.80 POLB (1.00) POLBSMN1; SMN2HTTRAB9AHIF1A
SCHEMBL20119352 0.78 SMN1; SMN2 (0.59) POLBSMN1; SMN2HTTHIF1ALMNA
SCHEMBL19082961 0.78 SMN1; SMN2 (0.54) POLBSMN1; SMN2HTTRAB9AHIF1A
Kinetin SCHEMBL15705 0.78 SMN1; SMN2 (0.66) POLBSMN1; SMN2HTTRAB9AHIF1A
Kinetin SCHEMBL29829493 0.78 SMN1; SMN2 (0.66) POLBSMN1; SMN2HTTRAB9AHIF1A
SCHEMBL13192090 0.77 SMN1; SMN2 (1.00) POLBSMN1; SMN2HTTRAB9AHIF1A
SCHEMBL4354437 0.77 JAK2 (0.68) SMN1; SMN2HTTRAB9ALMNATSHR
SCHEMBL28762132 0.76 TTBK1 (0.56) HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885SMN1; SMN2 11/4885HTT 326/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885SMN1; SMN2 11/4885HTT 326/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885SMN1; SMN2 11/4885HTT 326/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885SMN1; SMN2 11/4885HTT 326/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885SMN1; SMN2 11/4885HTT 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.